![Pharmaceutics | Free Full-Text | The Road to Better Management in Resistant Hypertension—Diagnostic and Therapeutic Insights Pharmaceutics | Free Full-Text | The Road to Better Management in Resistant Hypertension—Diagnostic and Therapeutic Insights](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-13-00714/article_deploy/html/images/pharmaceutics-13-00714-g001.png?1621029182)
Pharmaceutics | Free Full-Text | The Road to Better Management in Resistant Hypertension—Diagnostic and Therapeutic Insights
![Frontiers | Blood Pressure Changes Following Antihypertensive Medication Reduction, by Drug Class and Dose Chosen for Withdrawal: Exploratory Analysis of Data From the OPTiMISE Trial Frontiers | Blood Pressure Changes Following Antihypertensive Medication Reduction, by Drug Class and Dose Chosen for Withdrawal: Exploratory Analysis of Data From the OPTiMISE Trial](https://www.frontiersin.org/files/MyHome%20Article%20Library/619088/619088_Thumb_400.jpg)
Frontiers | Blood Pressure Changes Following Antihypertensive Medication Reduction, by Drug Class and Dose Chosen for Withdrawal: Exploratory Analysis of Data From the OPTiMISE Trial
![Co-treatment with clonidine and a GRK2 inhibitor prevented rebound hypertension and endothelial dysfunction after withdrawal in diabetes | Hypertension Research Co-treatment with clonidine and a GRK2 inhibitor prevented rebound hypertension and endothelial dysfunction after withdrawal in diabetes | Hypertension Research](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41440-018-0016-6/MediaObjects/41440_2018_16_Fig1_HTML.jpg)